The Risk of Fetal Loss in Family Members of Probands with Factor V Leiden Mutation

Summary

In order to investigate the risk of fetal loss in carriers of factor V Leiden who are family members of probands with this mutation, we performed a retrospective cohort study including 109 women who had been pregnant at least once and were family members of 61 probands with venous thromboembolism and a single identified factor V Leiden mutation. The rate of pregnancies ending in unexplained fetal loss, early miscarriage, late miscarriage or stillbirth in women with the factor V Leiden was compared with that of women with normal genotype. In the 65 women who were carriers of factor V Leiden 31 of the 191 pregnancies (16.2% per pregnancy ) resulted in unexplained fetal loss, as compared to 13 of the 121 pregnancies (10.7% per pregnancy) in the 44 non-carriers (relative risk, 1.5; 95% CI, 0.8-3.2). After the first trimester of pregnancy, 25 pregnancies (13.1% per pregnancy) among carriers of factor V Leiden ended in fetal loss, as compared to 7 (5.8% per pregnancy) among females with normal genotype (relative risk, 2.3; 95% CI, 1.01 to 5.1). We conclude that carriers of factor V Leiden who are family members of probands with this mutation have a statistically significant and clinically important risk of late miscarriage or stillbirth. Studies addressing the benefit-to-risk ratio of adopting routinary thromboprophylactic measures following the first trimester of pregnancy in these women are strongly indicated.

• References

• 1 Brenner B, Blumenfeld Z. Thrombophilia and fetal loss. Blood Rev. 1997; 11: 72-9.
• 2 Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W, Pabinger I, Legnani C, Scharrer I, Schulman S, van der Meer F J M. Increased fetal loss in women with heritable thrombophilia. Lancet. 1996; 348: 913-6.
• 3 Sanson B-J, Friederich P, Simioni P, Zanardi S, Huisman M, Girolami A, ten Cate J-W, Prins M. The risk of abortion and stillbirth in antithrombin, protein C and protein S deficient women. Thromb Haemost 1996; 75: 387-88.
• 4 Heijboer H, Brandjes DPM, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep vein thrombosis. N Engl J Med 1990; 323: 1512-6.
• 5 Koster T, Rosendaal F, de Ronde H, Briët E, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
• 6 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
• 7 Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol 1996; 92: 489-90.
• 8 Grandone E, Margaglione M, Colaizzo D, d’Addedda M, Cappucci G, Vecchione G, Sciannamé N, Pavone G, Di Minno G. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost. 1997; 77: 822-4.
• 9 Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE, Hill JA. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med. 1998; 128: 1000-3.
• 10 Dizon-Townson DS, Meline L, Nelson LM, Varner M, Ward K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol 1997; 177: 402-5.
• 11 Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A. The risk of recurrent venous thromboembolism in patients with an Arg506 → Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
• 12 Friederich PW, Sanson B-J, Simioni P, Zanardi S, Huisman MV, Kindt I, Prandoni P, Buller HR, Girolami A, Prins MH. Frequency of pregnancyrelated venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Int Med 1996; 125: 955-60.
• 13 Zanon E, Saracino MA, Simioni P, Cogo A, Fadin MA, Gavasso S, Girolami A. Prevalence of antiphospholipid antibodies and lupus anticoagulant in juvenile patients with objectively documented deep-vein thrombosis. Clin Appl Thromb Hemost 1996; 2: 69-73.
• 14 Simioni P, Prandoni P, Zanon E, Saracino MA, Scudeller A, Villalta S, Scarano L, Girolami B, Benedetti L, Girolami A. Deep venous thrombosis and lupus anticoagulant. A case control study. Thromb Haemost 1996; 76: 187-9.
• 15 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3í-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
• 16 Rai RS, Regan L, Chitolie A, Donald JG, Cohen H. Placental thrombosis and second trimester miscarriage in association with activated protein C resistance. Br J Obstet Gynaecol 1996; 103: 842-4.
• 17 Balasch J, Reverter JC, Fabregues F, Tassies D, Rafel M, Creus M, Vanrell JA. First-trimester repeated abortion is not associated with activated protein C resistance. Hum Reprod 1997; 12: 1094-7.
• 18 Kufferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing J. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9-13.